The UAB P30 Research and Translation Core Center consolidates a large number of externally funded cystic fibrosis (CF) research programs on our campus. During the first funding period, the P30 has made important contributions to multiple UAB laboratories pursuing research relevant to CFTR cellular and Structural biology and CF pathogenesis. By virtue of the NIH Center, translational research at our Institution has advanced significantly in the past four years The richness of CF basic science at UAB has grown in parallel with this translational expansion. The P30 Center has allowed investigators at UAB and collaborating sites to improve understanding of cystic fibrosis disease mechanism and furnished novel opportunities to aggressively apply this Information towards experimental therapeutics. This NIH Center includes three Scientific Cores that help organize efforts of CF faculty towards the common and essential goal of helping Individuals with CF. The Cores include: Core A: Cell Model and Assay Core (KL Kirk, PI); Core B: Animal Models Core (DM Bedwell, PI); and Core C: Clinical and Translational Core (SM Rowe, PI). Each Core provides leading-edge assays, specialized reagents and valved expertise. The P30 has also engaged new investigators through a Pilot and Feasibility mechanism integral to Center vitality. In addition to providing a platform from which junior and senior scientists are brought into the field, Pilot Projects serve as a means of rapidly testing exciting advances, particularly from the perspective of clinical translation. Two Pilot and Feasibility Projects are proposed: Project 1: SG Aller, PI. Structure-based correction of the major defect in cystic fibrosis; and Project 2: GA Caldwell, PI. Investigation of torsinA modulation as a therapeutic strategy for cystic fibrosis. Through these scientific initiatives, th P30 has enhanced a collaborative environment for cystic fibrosis research at UAB, and is well positioned to continue in this capacity in the future.
The UAB P30 embodies a well funded Research Base dedicated to expanding the boundaries of knowledge regarding cystic fibrosis pathogenesis and therapy. Progress is measured by innovative contributions and scientific discovery designed to improve the lives of patients with the disease.
|Brand, Jeffrey D; Lazrak, Ahmed; Trombley, John E et al. (2018) Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis. JCI Insight 3:|
|Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor. Int Forum Allergy Rhinol 8:577-583|
|Guimbellot, Jennifer S; Acosta, Edward P; Rowe, Steven M (2018) Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol 53:E6-E8|
|Solomon, George M; Bronsveld, Inez; Hayes, Kathryn et al. (2018) Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD). J Vis Exp :|
|Reeves, Emer P; O'Dwyer, Ciara A; Dunlea, Danielle M et al. (2018) Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med 198:1099-1102|
|McCormick, Lydia L; Phillips, Scott E; Kaza, Niroop et al. (2018) Maternal Smoking Induces Acquired CFTR Dysfunction in Neonatal Rats. Am J Respir Crit Care Med 198:672-674|
|Duncan, Gregg A; Kim, Namho; Colon-Cortes, Yanerys et al. (2018) An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304|
|Gelfond, Daniel; Heltshe, Sonya L; Skalland, Michelle et al. (2018) Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr 66:657-663|
|Birket, Susan E; Davis, Joy M; Fernandez, Courtney M et al. (2018) Development of an airway mucus defect in the cystic fibrosis rat. JCI Insight 3:|
|Shei, Ren-Jay; Peabody, Jacelyn E; Kaza, Niroop et al. (2018) The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr Opin Pharmacol 43:152-165|
Showing the most recent 10 out of 175 publications